si-Scrambled siRNA/shRNA/RNAi Lentivector (Target c)

i000238c500 ng


Unit quantity500 ng
Bacterial SelectionKanamycin
Mammalian Selection MarkerPuromycin
Product FeaturessiRNA (Target c)
SystemLentiviral Vector

Restriction Enzyme Digest and Sequencing

Selection MarkerPuromycin
Vector Map


  • Direct non-viral plasmid transfection for immediate expression
  • Package into Lentiviral particles for high efficiency transduction and stably integrated expression
Shipping Conditions

Shipped at ambient temperature

Shelf Life1 year (when at -20°C or below in a non-frost free freezer)
Storage Condition-20°C or below
CautionThis product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information.
Disclaimer1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final.
2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final.
3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s).
4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct.
5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression.
For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones.
abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.

Supporting Protocol





          There are no FAQs for this product yet!

          • Zhang, M., Wang, B., Urabe, G., Huang, Y., Plutzky, J., Kent, K. C., & Guo, L.-W. "The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation" Cellular Signalling 61:20–29 (2019). DOI: 10.1016/j.cellsig.2019.05.005.